120
Participants
Start Date
January 22, 2021
Primary Completion Date
June 5, 2025
Study Completion Date
December 31, 2025
UroLift
"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
Rezum
"The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra."
Weil Cornell Medical College, Cornell University, New York
NYU Winthrop Urology, Garden City
Comprehensive Urology, Royal Oak
UT Southwestern Medical Center, Dallas
Urology San Antonio, San Antonio
Urology Austin, Austin
Tower Urology, Los Angeles
Frimley Park Hospital, Frimley
NORFOLK and Norwich University Hospital, Norwich
Cambridge University Hospitals NHS Foundation Trust, Cambridge
NeoTract, Inc.
INDUSTRY